A week ago, Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) came out with a strong set of first-quarter numbers that ...

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

Viridian Therapeutics recently reported positive topline results from its REVEAL‑2 phase 3 trial of elegrobart in chronic thyroid eye disease, while also completing US$125,000,014 of common stock and ...

Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.

Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease May 5, 2026 8:00 ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today ...

Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.

In March, Viridian posted a phase 3 win for elegrobart in active TED, defined as patients who developed symptoms within 15 ...

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

By Siddhi Mahatole May 5 (Reuters) - Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock posted a 12.72% increment from a year ago, and a 51.76% year-to-date ...

Viridian Therapeutics' shares rose after the company said its treatment for thyroid eye disease met its primary endpoint in a recent trial. The stock gained 58% to $22.30 in premarket trading Tuesday.